読み込み中
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
前日終値
$10.52
+$0.31 · +3.04%
日中の時刻はETです。市場データは遅延する場合があります。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日中レンジ
現在 $10.52
52週レンジ
現在 $10.52
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
71
強気
リスク
53
やや高いリスク
モメンタム
67
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日中レンジ
現在 $10.52
52週レンジ
現在 $10.52
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 10.5万 USD | — | — | — | — |
| 粗利益 | −10.5万 USD | — | — | — | — |
| 研究開発 | 3371.9万 USD | 1938.5万 USD | 1652.6万 USD | 2446.8万 USD | 2911.5万 USD |
| 販売・一般管理 | 925.2万 USD | 816.3万 USD | 688.1万 USD | 809.7万 USD | 951.5万 USD |
| 営業費用 | 4286.6万 USD | 2754.8万 USD | 2340.7万 USD | 3256.5万 USD | 3863万 USD |
| 受取利息 | 250.5万 USD | 182.4万 USD | 158.4万 USD | 65.4万 USD | — |
| 支払利息 | — | — | — | — | 1.5万 USD |
| 減価償却費と償却費 | 10.5万 USD | 8.5万 USD | 15.1万 USD | 36.7万 USD | 46万 USD |
| 営業利益 | −4297.1万 USD | −2754.8万 USD | −2340.7万 USD | −3256.5万 USD | −3863万 USD |
| 純利益 | −1528.3万 USD | −6229.3万 USD | −2702.9万 USD | −4130.7万 USD | −4324.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$40.00
上昇余地（280.23%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3379.53万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1874.67万0.19%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1721.77万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1209.4万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO602.16万0.04%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO546.14万0.03%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB506.46万0.05%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA405.37万0.02%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
